Research programme: hepatitis C virus NS3/4A protein inhibitors - Phenomix

Drug Profile

Research programme: hepatitis C virus NS3/4A protein inhibitors - Phenomix

Alternative Names: PHX-B; PHX-C

Latest Information Update: 04 Feb 2011

Price : $50

At a glance

  • Originator Phenomix Corporation
  • Class Small molecules
  • Mechanism of Action Hepatitis C virus NS3 protein inhibitors; Hepatitis C virus NS4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 14 Mar 2007 NS3/4A viral protease inhibitors are available for licensing worldwide (
  • 13 Mar 2007 Preclinical trials in Hepatitis C treatment in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top